Microbot Medical Announces Successful Animal Study Utilizing Its LIBERTY™ Robotic System
August 17 2020 - 7:30AM
Microbot Medical Inc. (Nasdaq: MBOT), today announced the
successful conclusion of its feasibility animal study using the
Company’s LIBERTY™ Robotic System, the world’s first fully
disposable surgical robotic system. The study met all of its end
points with no intraoperative adverse events, which supports the
Company’s objectives to allow physicians to conduct a
catheter-based procedure from outside the catheterization
laboratory (cath-lab), avoiding radiation exposure, physical strain
and the risk of cross contamination. It was performed by two
leading physicians in the neuro vascular and peripheral vascular
intervention spaces, and the results demonstrated robust navigation
capabilities, intuitive usability and accurate deployment of
embolic agents, most of which was conducted remotely from the
cath-lab’s control room.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a18d5bb2-f23e-4e1a-a7e0-945da51172c6
https://www.globenewswire.com/NewsRoom/AttachmentNg/60931858-446a-41ec-9adc-67524506eeb4
“We continue to validate the
LIBERTY™ Robotic System and confirm our assertion that it has
the potential to revolutionize the robotic surgery space by
democratizing endoluminal procedures with enhanced clinical and
economical outcomes,” commented Harel Gadot, CEO, President and
Chairman. “The freedom from capital equipment, coupled with the
ability to operate LIBERTY™ remotely, especially in today’s
COVID-19 healthcare environment, will potentially reduce the cross
contamination between the surgical staff and patients on top of
reducing radiation exposure. Overall, we believe that we are in the
right market, at the right time and with the right solution.”
Mr. Gadot, along with other members of the
management team, will be sharing these results at the Needham
Virtual Med Tech & Diagnostics Conference being held today. A
copy of the investor presentation, which highlights the initial
results of the feasibility animal study, can be accessed via the
‘Investors’ section, under ‘Presentation + Resources’ of the
Company’s website at www.microbotmedical.com.
The Company believes that the
LIBERTY™ Robotic System, which was unveiled in January 2020,
is the world’s first fully disposable robotic system which features
a unique compact design; With the capability to be operated
remotely, it is being designed to reduce radiation exposure, the
physical strain to the physician as well as cross contamination
between the surgical staff and patients. In addition, incorporating
the technology the Company acquired from CardioSert into the
LIBERTY™ Robotic System, has the potential to eliminate the
use of multiple consumables through its “One & Done”
capabilities.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY™, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC) and in the prospectus
supplement related to the registered direct offering to be filed
with the SEC, which are or will be available on the SEC’s web site
at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by
law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Jul 2024 to Jul 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Jul 2023 to Jul 2024